{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:37:42Z","timestamp":1761917862506},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ijantimicag.2018.10.021","type":"journal-article","created":{"date-parts":[[2018,11,2]],"date-time":"2018-11-02T18:21:53Z","timestamp":1541182913000},"page":"284-293","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Managing invasive aspergillosis in haematological patients in the era of resistance polymerase chain reaction and increasing triazole resistance: A modelling study of different strategies"],"prefix":"10.1016","volume":"53","author":[{"given":"R.J.","family":"van de Peppel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.T.","family":"van der Beek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.G.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.G.J.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Wallinga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0001","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jinf.2018.02.012","article-title":"The burden of invasive aspergillosis in patients with haematological malignancy: a meta-analysis and systematic review","volume":"76","author":"van de Peppel","year":"2018","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0002","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2016.21.30.30300","article-title":"Emerging aspergillosis by azole-resistant Aspergillus fumigatus at an intensive care unit in the Netherlands, 2010 to 2013","volume":"21","author":"van Paassen","year":"2016","journal-title":"Euro Surveill"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0003","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.3201\/eid1710.110226","article-title":"Clinical implications of azole resistance in Aspergillus fumigatus, The Netherlands, 2007\u20132009","volume":"17","author":"van der Linden","year":"2011","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0004","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S1473-3099(09)70265-8","article-title":"Azole resistance in Aspergillus fumigatus: a side-effect of environmental fungicide use?","volume":"9","author":"Verweij","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0005","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/cid\/cit320","article-title":"Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles","volume":"57","author":"van der Linden","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0006","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1093\/jac\/dku566","article-title":"Emergence of azole-resistant invasive aspergillosis in HSCT recipients in Germany","volume":"70","author":"Steinmann","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0007","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0008","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0009","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1038\/bmt.2017.71","article-title":"A new time-dependent approach for assessment of the impact of invasive aspergillosis shows effect on short- but not on long-term survival of patients with AML or high-risk MDS","volume":"52","author":"van de Peppel","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0010","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1093\/cid\/ciu911","volume":"60","author":"Herbrecht","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0011","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Cornely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0012","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1093\/jac\/dkw323","article-title":"PCR-based detection of Aspergillus fumigatus Cyp51A mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay(R) in 201 patients with haematological disease suspected for invasive aspergillosis","volume":"71","author":"Chong","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0013","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1128\/JCM.00520-17","article-title":"Culture-based methods and molecular tools for azole-resistant Aspergillus fumigatus detection in a Belgian university hospital","volume":"55","author":"Montesinos","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0014","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jinf.2017.11.011","article-title":"Improving the diagnosis of invasive aspergillosis by the detection of aspergillus in broncho-alveolar lavage fluid: comparison of non-culture-based assays","volume":"76","author":"Guegan","year":"2018","journal-title":"J Infect"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0015","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1128\/JCM.01032-17","article-title":"Molecular diagnosis of invasive aspergillosis and detection of azole resistance by a newly commercialized PCR Kit","volume":"55","author":"Dannaoui","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0016","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1086\/521942","article-title":"Comparison of 2 studies of treatment of invasive aspergillosis","volume":"45","author":"Denning","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0017","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1093\/jac\/dkv177","article-title":"High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients","volume":"70","author":"Fuhren","year":"2015","journal-title":"J\u00a0Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0018","doi-asserted-by":"crossref","first-page":"O952","DOI":"10.1111\/1469-0691.12688","article-title":"Breakthrough invasive fungal disease in patients receiving posaconazole primary prophylaxis: a 4-year study","volume":"20","author":"Lerolle","year":"2014","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 3","key":"10.1016\/j.ijantimicag.2018.10.021_bib0019","doi-asserted-by":"crossref","first-page":"S188","DOI":"10.1086\/376524","article-title":"Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001","volume":"37","author":"Steinbach","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0020","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1016\/j.ijid.2011.10.004","article-title":"The role of combination antifungal therapy in the treatment of invasive aspergillosis: a systematic review","volume":"16","author":"Garbati","year":"2012","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0021","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3389\/fmicb.2018.00555","article-title":"Comparison of two molecular assays for detection and characterization of Aspergillus fumigatus triazole resistance and Cyp51A mutations in clinical isolates and primary clinical samples of immunocompromised patients","volume":"9","author":"Postina","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0022","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1128\/JCM.00467-14","article-title":"Performance of galactomannan, beta-d-glucan, aspergillus lateral-flow device, conventional culture, and PCR tests with bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis","volume":"52","author":"Hoenigl","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0023","first-page":"528","article-title":"Galactomannan testing and aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis","volume":"55","author":"Eigl","year":"2017","journal-title":"Med Mycol"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0024","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.cmi.2016.06.021","volume":"22","author":"Boch","year":"2016","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0025","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/j.1439-0507.2005.01101.x","article-title":"Candidosis and aspergillosis as autopsy findings from 1994 to 2003","volume":"48","author":"Schwesinger","year":"2005","journal-title":"Mycoses"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0026","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00277-002-0599-4","article-title":"Clinical applicability of the new EORTC\/MSG classification for invasive pulmonary aspergillosis in patients with hematological malignancies and autopsy-confirmed invasive aspergillosis","volume":"82","author":"Subira","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0027","first-page":"12","article-title":"Combination antifungal therapy for invasive aspergillosis revisited","volume":"2","author":"Panackal","year":"2015","journal-title":"Med Mycol Open Access"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0028","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijid.2014.07.007","article-title":"Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis","volume":"28","author":"Panackal","year":"2014","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0029","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination antifungal therapy for invasive aspergillosis: a randomized trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0030","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0031","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1201-9712(99)90038-3","article-title":"Amphotericin B with and without itraconazole for invasive aspergillosis: a three-year retrospective study","volume":"3","author":"Popp","year":"1999","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0032","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2018.10.021_bib0033","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/cid\/ciw585","article-title":"Real-life use of isavuconazole in patients intolerant to other azoles","volume":"63","author":"Ordaya","year":"2016","journal-title":"Clin Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303133?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918303133?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,3,6]],"date-time":"2019-03-06T05:14:10Z","timestamp":1551849250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918303133"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0924857918303133"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.10.021","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Managing invasive aspergillosis in haematological patients in the era of resistance polymerase chain reaction and increasing triazole resistance: A modelling study of different strategies","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}